Seagen Inc.
https://www.seagen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Seagen Inc.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.
Genmab's Growth Strategy: Embracing A ‘Super Rational, Data-Driven' Mindset
The “Genmab sauce” will be crucial as the Danish biotech loads up on late-stage assets, grows its capabilities and expands into immunology and inflammation.
A Sneak Peak At Pfizer’s Next-Generation ADC Pipeline
Antibody-drug conjugates remain a hot area of cancer drug development and Pfizer showed investors some of the novel targets and improved payloads it is advancing.
Taking On Vyvgart In Myasthenia Gravis
Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Alpine Biosciences
- Biomira
- Oncothyreon, Inc.
- Cascadian Therapeutics, Inc.
- Seattle Genetics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice